TET-2 mutations (Ten-eleven translocation 2) were originally described in myeloid malignancies, such as myelodysplastic syndromes (MDS), chronic myelomonocytic leukemias (CMML), and acute myeloid leukemias (AML). Here, TET2 is linked to acute myeloid leukemia.